Yarrow

Yarrow is a biotechnology company dedicated to developing next-generation antisense oligonucleotide (ASO) therapies for severe, genetically defined central nervous system (CNS) disorders. Incubated by Atlas Venture, the company utilizes a proprietary platform to engineer ASOs with enhanced pharmacological properties, including improved potency and broader distribution throughout the brain. Yarrow's research focuses on addressing the root causes of rare neurodevelopmental and neurodegenerative diseases that currently lack effective treatments. By combining deep expertise in RNA biology and neuroscience, the company aims to create a pipeline of transformative medicines for patients with high unmet medical needs. The company is headquartered in the biotech hub of Cambridge, Massachusetts.